TD Cowen Reaffirms Their Buy Rating on Repare Therapeutics (RPTX)
Piper Sandler Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $25
Bloom Burton Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $15
TD Cowen Maintains Repare Therapeutics(RPTX.US) With Buy Rating
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Express News | Repare Therapeutics Inc - Overall Response of 18.2% in Heavily Pretreated Patients
Express News | Repare Therapeutics Inc: Safety Profile of Combination Consistent With Folfiri Alone
Express News | Repare Therapeutics Announces Positive Initial Data at Esmo Gi From Phase 1 Minotaur Trial Evaluating Lunresertib in Combination With Folfiri
Remix Therapeutics Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director
Capital One Financial Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $21
Express News | Foundation Medicine: Partnership to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
Express News | Foundation Medicine: Co Announces Partnership With Repare Therapeutics
Foundation Medicine Announces Partnership With Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
Express News | Repare Therapeutics Inc- Repare Expects a Potential Data Readout in Camonsertib Monotherapy Nsclc Expansion in 2025
Express News | Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of Tresr Clinical Trial
H.C. Wainwright Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $10
Repare Gets FDA Fast Track Status for Ovarian Cancer Drug Combo
Express News | Repare Therapeutics Receives FDA Fast Track Designation For Lunresertib In Combination With Camonsertib For Platinum-Resistant Ovarian Cancer
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination With Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference